Johnson & Johnson $JNJ Shares Sold by Cape ANN Savings Bank

Cape ANN Savings Bank reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.8% in the 2nd quarter, HoldingsChannel reports. The fund owned 18,739 shares of the company’s stock after selling 335 shares during the quarter. Johnson & Johnson accounts for approximately 1.7% of Cape ANN Savings Bank’s investment portfolio, making the stock its 14th biggest holding. Cape ANN Savings Bank’s holdings in Johnson & Johnson were worth $2,862,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in JNJ. Highline Wealth Partners LLC raised its stake in Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after acquiring an additional 86 shares in the last quarter. Stone House Investment Management LLC purchased a new position in shares of Johnson & Johnson during the first quarter worth about $47,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson during the first quarter worth about $48,000. von Borstel & Associates Inc. purchased a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 1.4%

JNJ stock opened at $188.51 on Monday. The stock has a market capitalization of $453.98 billion, a PE ratio of 20.16, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. The company has a fifty day moving average of $176.18 and a 200-day moving average of $162.83. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a one year low of $140.68 and a one year high of $189.78.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. During the same period in the prior year, the company posted $2.82 earnings per share. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Analysts Set New Price Targets

JNJ has been the topic of several research analyst reports. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. HSBC lifted their target price on shares of Johnson & Johnson from $188.00 to $210.00 in a report on Tuesday, September 30th. Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price target for the stock from $167.00 to $206.00 in a research note on Tuesday, September 23rd. JPMorgan Chase & Co. lifted their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Tuesday, September 16th. Finally, Citigroup upped their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “buy” rating in a report on Thursday, August 21st. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $188.88.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.